Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer

Inclusion Criteria: * Patients must have pathological diagnosis of renal cell carcinoma that is metastatic or surgically unresectable; the histology must be clear cell carcinoma or predominant clear cell carcinoma * Patients may have received up to two prior therapies including vascular endothelial growth factor (VEGF), mammalian target of rapamycin (mTOR) and programmed cell death (PD)-1/PD ligand 1 (L1) inhibitors; prior palliative radiation to metastatic lesion(s) is permitted, provided there is at least one measurable and/or evaluable lesion(s) that has not been irradiated * Patients must have measurable or evaluable disease * Eastern Cooperative Oncology Group (ECOG) performance status 0 * Life expectancy of greater than 6 months * Hemoglobin \>= 12 g/dL * Leukocytes \>= 3,000/mm\^3 * Absolute neutrophil count \>= 1,500/mm\^3 * Platelets \>= 100,000/mm\^3 * Total bilirubin =\< 1.5 x laboratory upper limit of normal * Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SGPT\]) =\< 2.5 x laboratory upper limit of normal * Creatinine =\< 1.5 x laboratory upper limit of normal or calculated creatinine clearance of \>= 50 ml/min * Lactate dehydrogenase (LDH) within normal limits (WNL) * Corrected calcium =\< 10 mg/dL * Prothrombin time (PT)/international normalized ratio (INR) =\< 1.5 * Urine protein \< 1+; if \>= 1+, 24 hour urine protein should be obtained and should be …